Suven Life Sciences to launch phase 3 clinical trial for Masupirdine

Suven Life Sciences is set to launch a phase 3 clinical trial for its 5-HT6 antagonist SUVN-502 (Masupirdine) for the treatment of agitation and aggression ... Read More